Skip to content

Study · Non-randomized trial · n = 10 · 2025

8 results

Outcomes of glepaglutide on intestinal absorption and parenteral support in patients with short bowel syndrome.

Pinar I, Nielsen TSS, Soldbro L, Hvistendahl MK, Berner-Hansen M, Jeppesen PB

Clinical nutrition ESPEN6 Aug 2025Cited by 3 (Europe PMC)

PMID40774623 (opens in a new tab)DOI10.1016/j.clnesp.2025.08.006 (opens in a new tab)PepBankPUB-40774623
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide numerically increased intestinal wet weight absorption by 398 g/day from baseline (P = 0.0585).

    In plain wordsIn patients with short bowel syndrome, glepaglutide numerically increased intestinal wet weight absorption from baseline.

    Peptide
    Glepaglutide
    Outcome
    IncreaseIntestinal wet weight absorption
    Study

    n = 10

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    10 mg once weekly · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Change in intestinal wet weight absorption
    398 g/day
    mean change from baseline at week 24

    Source sentences

    Summary
    At week 24, mean numerical increase in intestinal wet weight absorption was 398 g/day (P = 0.0585) and mean energy absorption 1038 kJ/day (P = 0.0215).
    1 context sentence
    Summary · context
    In this single-center, open-label, phase 3b study, 10 patients with SBS - 8 with intestinal failure (SBS-IF) and 2 with intestinal insufficiency - received glepaglutide 10 mg once weekly via subcutaneous injection.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide increased energy absorption by 1038 kJ/day from baseline (P = 0.0215).

    In plain wordsIn patients with short bowel syndrome, glepaglutide increased energy absorption from baseline.

    Peptide
    Glepaglutide
    Outcome
    IncreaseEnergy absorption
    Study

    n = 10

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    10 mg once weekly · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Change in energy absorption
    1038 kJ/day
    mean change from baseline at week 24

    Source sentences

    Summary
    At week 24, mean numerical increase in intestinal wet weight absorption was 398 g/day (P = 0.0585) and mean energy absorption 1038 kJ/day (P = 0.0215).
    1 context sentence
    Summary · context
    In this single-center, open-label, phase 3b study, 10 patients with SBS - 8 with intestinal failure (SBS-IF) and 2 with intestinal insufficiency - received glepaglutide 10 mg once weekly via subcutaneous injection.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide improved electrolyte and macronutrient absorption from baseline.

    In plain wordsIn patients with short bowel syndrome, glepaglutide improved electrolyte and macronutrient absorption from baseline.

    Peptide
    Glepaglutide
    Outcome
    IncreaseElectrolyte and macronutrient absorption
    Study

    n = 10

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    10 mg once weekly · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements occurred in electrolyte and macronutrient absorption.
    1 context sentence
    Summary · context
    In this single-center, open-label, phase 3b study, 10 patients with SBS - 8 with intestinal failure (SBS-IF) and 2 with intestinal insufficiency - received glepaglutide 10 mg once weekly via subcutaneous injection.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with short bowel syndrome, body composition remained stable during glepaglutide treatment.

    In plain wordsIn patients with short bowel syndrome, body composition remained stable during glepaglutide treatment.

    Peptide
    Glepaglutide
    Outcome
    No significant changeBody composition
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    10 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Body composition and weight remained stable, and glepaglutide demonstrated a manageable safety profile.
    1 context sentence
    Summary · context
    In this single-center, open-label, phase 3b study, 10 patients with SBS - 8 with intestinal failure (SBS-IF) and 2 with intestinal insufficiency - received glepaglutide 10 mg once weekly via subcutaneous injection.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with short bowel syndrome, body weight remained stable during glepaglutide treatment.

    In plain wordsIn patients with short bowel syndrome, body weight remained stable during glepaglutide treatment.

    Peptide
    Glepaglutide
    Outcome
    No significant changeBody weight
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Body composition and weight remained stable, and glepaglutide demonstrated a manageable safety profile.
    1 context sentence
    Summary · context
    In this single-center, open-label, phase 3b study, 10 patients with SBS - 8 with intestinal failure (SBS-IF) and 2 with intestinal insufficiency - received glepaglutide 10 mg once weekly via subcutaneous injection.
  6. 06HumanNon-randomized trialSafety outcome

    In patients with short bowel syndrome, glepaglutide 10 mg once weekly was reported to have a manageable safety profile after 52 weeks of treatment.

    In plain wordsIn patients with short bowel syndrome, glepaglutide showed a manageable safety profile.

    Peptide
    Glepaglutide
    Outcome
    Not applicableSafety profile
    Study

    n = 10

    Outcome group
    Adverse events · Whole body
    Studied dose
    10 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Body composition and weight remained stable, and glepaglutide demonstrated a manageable safety profile.
    1 context sentence
    Summary · context
    In this single-center, open-label, phase 3b study, 10 patients with SBS - 8 with intestinal failure (SBS-IF) and 2 with intestinal insufficiency - received glepaglutide 10 mg once weekly via subcutaneous injection.
  7. 07HumanNon-randomized trialEfficacy outcome

    In patients with short bowel syndrome, mean parenteral support volume decreased by 800 mL/day from baseline with glepaglutide (P = 0.0106).

    In plain wordsIn patients with short bowel syndrome, parenteral support volume decreased from baseline with glepaglutide.

    Peptide
    Glepaglutide
    Outcome
    DecreaseParenteral support volume
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    10 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    Reduction in parenteral support volume
    800 mL/day
    mean reduction from baseline at week 52

    Source sentences

    Summary
    At week 52, mean PS volume was reduced by 800 mL/day (P = 0.0106) with a reduction in mean PS energy content of 866 kJ/day (P = 0.0103).
    1 context sentence
    Summary · context
    In this single-center, open-label, phase 3b study, 10 patients with SBS - 8 with intestinal failure (SBS-IF) and 2 with intestinal insufficiency - received glepaglutide 10 mg once weekly via subcutaneous injection.
  8. 08HumanNon-randomized trialEfficacy outcome

    In patients with short bowel syndrome, mean parenteral support energy content decreased by 866 kJ/day from baseline with glepaglutide (P = 0.0103).

    In plain wordsIn patients with short bowel syndrome, parenteral support energy content decreased from baseline with glepaglutide.

    Peptide
    Glepaglutide
    Outcome
    DecreaseParenteral support energy content
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    10 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    Reduction in parenteral support energy content
    866 kJ/day
    mean reduction from baseline at week 52

    Source sentences

    Summary
    At week 52, mean PS volume was reduced by 800 mL/day (P = 0.0106) with a reduction in mean PS energy content of 866 kJ/day (P = 0.0103).
    1 context sentence
    Summary · context
    In this single-center, open-label, phase 3b study, 10 patients with SBS - 8 with intestinal failure (SBS-IF) and 2 with intestinal insufficiency - received glepaglutide 10 mg once weekly via subcutaneous injection.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.